Point of Care Molecular Diagnostics Market Share

ID: MRFR/HC/9964-HCR

200 Pages

Rahul Gotadki

October 2025

Point of Care Molecular Diagnostics Market Research Report By Product Type (PCR Tests, Nucleic Acid Amplification Tests, Microarray, Next-Generation Sequencing, Other Genetic Tests), By Application (Infectious Diseases, Genetic Testing, Cancer Diagnosis, Metabolic Disorders), By End Use (Hospitals, Diagnostic Laboratories, Home Care Settings, Outpatient Clinics), By Technology (Isothermal Ampli...

Point of Care Molecular Diagnostics Market Infographic

Summary Table of Contents Segmentation Download PDF

Market Share

Point of Care Molecular Diagnostics Market Share Analysis

The Point Of Care Molecular Diagnostics Market is a dynamic space for companies that adopt various strategies for gaining market share because it is at the cutting edge of healthcare technological advancement. One such strategy involves technological innovation of molecular diagnostic platforms. Companies spend heavily on research and development to bring forth small-sized, quick-to-use POCMDs (point-of-care molecular diagnostic) devices into market. These companies are trying to win over health providers and institutions who look for prompt diagnostics with regard to infectious diseases like tuberculosis, genetic disorders such as Down's syndrome, or cancer.

Positioning of market share within the point of care molecular diagnostics’ market is influenced by the adopted pricing strategies. This may involve cost leadership approach that ensures competitive prices for point-of-care molecular diagnostics to cater for different healthcare facilities in regions with strained budgets. On the other hand, premium pricing strategies are likely to be used by firms whose main focus is on the sensitivity, specificity or unique aspects of their molecular diagnostic technologies with a target group consisting of health institutions and practitioners who look at putting in place quality and advanced point-of-care testing solutions.

Different companies segment the Point Of Care Molecular Diagnostics Market according to clinical settings or applications. For example, some devices might have been developed specifically for rapid genetic mutation identification while others are meant for use in infectious disease testing as well as real-time monitoring of treatment response among other applications. By so doing such firms like Biosite can establish themselves as specialized players within the Point of Care Molecular Diagnostics Market and accordingly offer medical solutions catering to diverse requirements of patients as well as medical practitioners.

Besides, distribution channel strategies play an important role in making sure that point-of-care molecular diagnostics are available everywhere. This involves establishment of business relationships between companies and clinics, primary care providers as well as urgent care centers. Digital means currently provide more efficiency and accessibility among health professionals using point-of-care molecular testing through product ordering platforms, training support systems and connectivity networks.

The above mentioned areas are important for those organizations which want to maintain or increase their market share within Point of Care Molecular Diagnostics industry. Technology advancements, automation, demand for innovative solutions in decentralized testing drive change within molecular diagnostic industry all requiring continuous research efforts from industry players. Unilever is one company that appreciates this aspect because it has invested over 1 billion Euros in its research department hence coming up with products like detergent waste reduction sachets.

Market Highlights

Author

Rahul Gotadki

Assistant Manager

He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

Get In Touch

FAQs

What is the projected market size of the Global Point of Care Molecular Diagnostics Market in 2024?

The Global Point of Care Molecular Diagnostics Market is expected to be valued at 6.25 USD Billion in 2024.

How much will the Global Point of Care Molecular Diagnostics Market be valued by 2035?

By 2035, the market is anticipated to reach a valuation of 15.0 USD Billion.

What is the expected CAGR for the Global Point of Care Molecular Diagnostics Market during the forecast period of 2025 to 2035?

The market is projected to grow at a CAGR of 8.28% from 2025 to 2035.

Which region is expected to have the largest market share in the Global Point of Care Molecular Diagnostics Market in 2024?

North America is expected to hold the largest market share, valued at 2.75 USD Billion in 2024.

What is the anticipated market size for Europe in the Global Point of Care Molecular Diagnostics Market in 2035?

Europe is estimated to reach a market size of 3.8 USD Billion by 2035.

What are the projected values for PCR Tests in the Global Point of Care Molecular Diagnostics Market for 2024 and 2035?

PCR Tests are projected to be valued at 2.0 USD Billion in 2024 and 4.7 USD Billion in 2035.

Who are the key players in the Global Point of Care Molecular Diagnostics Market?

Major players include Hologic, BD, Thermo Fisher Scientific, BioMérieux, Roche, and others.

What is the expected market growth rate for the Point of Care Molecular Diagnostics Market in the APAC region from 2024 to 2035?

The APAC region is expected to grow significantly, reaching a market value of 3.5 USD Billion by 2035.

What will be the market size for Nucleic Acid Amplification Tests in 2035?

Nucleic Acid Amplification Tests are projected to be valued at 3.6 USD Billion in 2035.

What challenges could impact the Global Point of Care Molecular Diagnostics Market?

Challenges may include regulatory hurdles, technological advancements, and market competition.

1. Market Overview

2. Market Trends

3. Market Segment Insights

4. Key Players and Competitive Insights

5. Industry Developments

6. Market Segmentation

7. Report Scope

8. Market Highlights

9. FAQs

Customize Report

Certified Researchers

Market Summary

As per MRFR analysis, the Point of Care Molecular Diagnostics Market was estimated at 6.248 USD Billion in 2024. The Point of Care Molecular Diagnostics industry is projected to grow from 6.765 USD Billion in 2025 to 14.99 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 8.28 during the forecast period 2025 - 2035.

Key Market Trends & Highlights

The Point of Care Molecular Diagnostics Market is experiencing robust growth driven by technological advancements and a shift towards personalized medicine.

North America remains the largest market for point of care molecular diagnostics, driven by advanced healthcare infrastructure.
Asia-Pacific is emerging as the fastest-growing region, fueled by increasing investments in healthcare technology.
PCR tests dominate the market as the largest segment, while next-generation sequencing is rapidly gaining traction as the fastest-growing segment.
Rising demand for rapid diagnostics and increased prevalence of infectious diseases are key drivers propelling market expansion.

Point of Care Molecular Diagnostics Market

CAGR

8.28%

Market Size & Forecast

2024 Market Size	6.248 (USD Billion)
2035 Market Size	14.99 (USD Billion)
CAGR (2025 - 2035)	8.28%
Largest Regional Market Share in 2024	North America

Major Players

Abbott Laboratories (US), Roche Diagnostics (CH), Thermo Fisher Scientific (US), Cepheid (US), Hologic, Inc. (US), Qiagen N.V. (NL), BD (Becton, Dickinson and Company) (US), GenMark Diagnostics (US)

Market Trends

The Point of Care Molecular Diagnostics Market is currently experiencing a transformative phase, driven by advancements in technology and an increasing demand for rapid diagnostic solutions. This market encompasses a range of diagnostic tools that enable healthcare professionals to conduct tests at or near the site of patient care. The convenience and speed of these tests are appealing, as they facilitate timely decision-making in clinical settings. Furthermore, the integration of molecular techniques enhances the accuracy and sensitivity of results, which is crucial for effective patient management. As healthcare systems evolve, the emphasis on personalized medicine and point-of-care testing is likely to grow, indicating a shift towards more patient-centered approaches in diagnostics. In addition to technological advancements, the Point of Care Molecular Diagnostics Market is influenced by changing healthcare policies and an increasing focus on preventive care. Governments and health organizations are recognizing the importance of early detection and intervention, which could lead to a greater adoption of point-of-care testing solutions. Moreover, the rise of telemedicine and remote patient monitoring may further propel the demand for these diagnostic tools, as they align with the need for accessible and efficient healthcare services. Overall, the market appears poised for growth, with various factors converging to enhance its relevance in modern healthcare delivery.

Technological Advancements

The Point of Care Molecular Diagnostics Market is witnessing rapid technological innovations that enhance the capabilities of diagnostic tools. These advancements include the development of portable devices and improved assay techniques, which allow for faster and more accurate results. Such innovations are likely to increase the adoption of point-of-care testing in diverse healthcare settings.

Shift Towards Personalized Medicine

There is a noticeable trend towards personalized medicine within the Point of Care Molecular Diagnostics Market. This approach tailors medical treatment to individual characteristics, needs, and preferences, which is facilitated by molecular diagnostics. As healthcare providers seek to offer more customized care, the demand for these diagnostic solutions is expected to rise.

Integration with Telehealth Services

The integration of point-of-care molecular diagnostics with telehealth services is emerging as a significant trend. This combination allows for remote testing and monitoring, making healthcare more accessible. As telehealth continues to expand, the synergy with point-of-care diagnostics could enhance patient engagement and streamline healthcare delivery.

The ongoing evolution of point-of-care molecular diagnostics is poised to enhance the speed and accuracy of disease detection, thereby transforming patient management and healthcare delivery.

U.S. Food and Drug Administration (FDA)

Point of Care Molecular Diagnostics Market Market Drivers

Supportive Regulatory Environment

The Point of Care Molecular Diagnostics Market is benefiting from a supportive regulatory environment that encourages innovation and adoption of new technologies. Regulatory bodies are increasingly recognizing the importance of rapid diagnostics in improving patient care and are streamlining approval processes for point of care devices. This trend is likely to facilitate the entry of novel diagnostic solutions into the market, thereby expanding the range of available options for healthcare providers. The favorable regulatory landscape is expected to contribute to a projected market growth of approximately 15% annually over the next five years. As regulations evolve to support the integration of advanced molecular diagnostics into routine practice, the industry is poised for substantial expansion.

Rising Demand for Rapid Diagnostics

The Point of Care Molecular Diagnostics Market is experiencing a notable surge in demand for rapid diagnostic solutions. This trend is largely driven by the need for timely and accurate results in various healthcare settings. As healthcare providers increasingly prioritize quick decision-making, the market for point of care diagnostics is projected to grow significantly. According to recent estimates, the market is expected to reach a valuation of approximately USD 10 billion by 2026. This growth is indicative of a broader shift towards immediate patient care, where molecular diagnostics play a crucial role in enhancing treatment outcomes. The ability to deliver results within minutes rather than days is transforming patient management, thereby solidifying the importance of point of care molecular diagnostics.

Growing Focus on Preventive Healthcare

The Point of Care Molecular Diagnostics Market is benefiting from a growing emphasis on preventive healthcare measures. As healthcare systems worldwide shift towards proactive management of health, the demand for early detection and diagnosis is increasing. Molecular diagnostics offer the potential to identify diseases at their nascent stages, allowing for timely interventions that can significantly improve patient outcomes. This trend is reflected in the increasing investments in point of care technologies, which are projected to reach USD 5 billion by 2025. The ability to conduct tests in various settings, including homes and community clinics, aligns with the broader goals of preventive healthcare, thereby driving the adoption of molecular diagnostics in diverse populations.

Increased Prevalence of Infectious Diseases

The Point of Care Molecular Diagnostics Market is significantly influenced by the rising prevalence of infectious diseases. As the global burden of diseases such as tuberculosis, HIV, and hepatitis continues to escalate, there is an urgent need for effective diagnostic tools that can be deployed at the point of care. The World Health Organization has reported that infectious diseases account for a substantial percentage of global mortality, underscoring the necessity for rapid and accurate diagnostics. This scenario is likely to propel the market forward, as healthcare systems seek to implement molecular diagnostics that can provide immediate results, thus facilitating timely treatment interventions. The integration of these technologies into routine healthcare practices is expected to enhance disease management and control efforts.

Technological Innovations in Diagnostic Tools

The Point of Care Molecular Diagnostics Market is witnessing a wave of technological innovations that are enhancing the capabilities of diagnostic tools. Advances in microfluidics, nanotechnology, and biosensors are enabling the development of more sensitive and specific tests that can be performed at the point of care. These innovations are not only improving the accuracy of results but also expanding the range of detectable conditions. As a result, the market is projected to grow at a compound annual growth rate of over 10% in the coming years. The integration of artificial intelligence and machine learning into diagnostic processes is further streamlining workflows and enhancing decision-making, making point of care molecular diagnostics an increasingly attractive option for healthcare providers.

Market Segment Insights

By Type: PCR Tests (Largest) vs. Next-Generation Sequencing (Fastest-Growing)

In the Point of Care Molecular Diagnostics Market, PCR Tests stand as the largest segment, making a significant contribution to the overall market share. Accounting for a considerable portion, PCR technology's established reliability has solidified its position, making it a go-to method for rapid diagnostics. Meanwhile, Nucleic Acid Amplification Tests and Microarray technologies also find a niche but do not capture the same level of prevalence as PCR.

Technology: PCR Tests (Dominant) vs. Next-Generation Sequencing (Emerging)

PCR Tests are widely recognized for their speed and accuracy, becoming the dominant technology in the Point of Care Molecular Diagnostics arena. They are frequently used for detecting infectious diseases due to their fast turnaround times and effectiveness in amplifying minute amounts of genetic material. Conversely, Next-Generation Sequencing (NGS) represents an emerging technology that is swiftly gaining traction for its ability to provide comprehensive genomic data. NGS is particularly favored in precision medicine and research, indicating a shift in diagnostic approaches. The growing demand for personalized medicine and advanced pathogen detection fuels NGS's rapid growth, making it a significant player in the future of point-of-care diagnostics.

By Application: Infectious Diseases (Largest) vs. Cancer Diagnosis (Fastest-Growing)

The Point of Care Molecular Diagnostics market exhibits a diverse distribution of applications, with Infectious Diseases leading as the largest segment. This application is heavily utilized in rapid diagnostics, catering to the immediate need for test results in various healthcare settings. On the other hand, Cancer Diagnosis is positioned as the fastest-growing segment, reflecting an increase in demand for early detection technologies and personalized medicine. As awareness surrounding cancer screening rises, this segment is expected to gain momentum in the coming years. Growth trends in the application segment of Point of Care Molecular Diagnostics are significantly shaped by advancements in technology and increasing healthcare expenditure. Infectious Diseases remain a priority due to ongoing public health challenges, driving research and development in this area. Conversely, the surge in the Cancer Diagnosis segment can be attributed to a growing aging population and a heightened emphasis on preventive healthcare. Innovations such as liquid biopsy and advanced biomarker identification are propelling the market forward, marking a transition toward more patient-centric diagnostic approaches.

Infectious Diseases (Dominant) vs. Cancer Diagnosis (Emerging)

Infectious Diseases stand as the dominant application in the Point of Care Molecular Diagnostics market, serving crucial roles in the timely detection of conditions such as COVID-19, influenza, and other communicable diseases. The convenience of quick testing in various settings enhances patient outcomes and reduces the burden on healthcare systems. Conversely, Cancer Diagnosis is emerging as a vital area of focus, driven by enhanced methods for early detection and treatment customization. This segment's growth is bolstered by evolving technologies and increased awareness around the importance of early diagnosis. As molecular diagnostics continue to evolve, the significance of both sectors will likely expand, ensuring comprehensive patient care and effective disease management.

By End Use: Hospitals (Largest) vs. Diagnostic Laboratories (Fastest-Growing)

In the Point of Care Molecular Diagnostics Market, the distribution of market share is prominently tilted towards hospitals, which account for the largest segment due to their high patient turnover and comprehensive diagnostic capabilities. This segment benefits from the integration of advanced diagnostic technologies and the increasing demand for rapid diagnostics in acute care settings, reinforcing its significant position in the market. In contrast, diagnostic laboratories are emerging as the fastest-growing segment, driven by their capacity for specialized testing and the rising reliance on diagnostic accuracy in disease identification and management. The growth trends within this segment are primarily influenced by the escalating need for timely and accurate diagnostic results. Factors such as the increasing prevalence of infectious diseases, advancements in molecular testing techniques, and the growing emphasis on personalized medicine are propelling the expansion of both hospitals and diagnostic laboratories. Additionally, government initiatives to enhance healthcare infrastructure and accessibility are expected to further accelerate market growth in these areas, improving overall patient outcomes and operational efficiency.

Hospitals (Dominant) vs. Diagnostic Laboratories (Emerging)

Hospitals, as the dominant segment in the Point of Care Molecular Diagnostics Market, are central to the delivery of acute and emergency care, where swift diagnostic results are crucial for effective patient management. Equipped with state-of-the-art technologies, hospitals can perform a wide array of tests, facilitating immediate treatment decisions. Meanwhile, diagnostic laboratories are positioned as an emerging segment, focusing on specialized molecular tests that cater to niche diagnostics and personalized medicine. Their agility in adopting new testing platforms and methodologies allows them to respond quickly to emerging health challenges. The collaboration between hospitals and laboratories enhances the overall diagnostic ecosystem, offering comprehensive care solutions to patients.

By Technology: Polymerase Chain Reaction (Largest) vs. CRISPR Technology (Fastest-Growing)

The Point of Care Molecular Diagnostics Market is increasingly shaped by key technological segments including Isothermal Amplification, Polymerase Chain Reaction (PCR), Sanger Sequencing, and CRISPR Technology. Among these, PCR remains the largest due to its established usage in various diagnostic testing applications. Isothermal amplification and Sanger sequencing also play significant roles, but they attract a smaller market share. Meanwhile, CRISPR technology is rapidly gaining traction, benefiting from its innovative approach and versatility in diagnostic applications.

Technology: PCR (Dominant) vs. CRISPR Technology (Emerging)

In the technology segment of Point of Care Molecular Diagnostics, Polymerase Chain Reaction (PCR) stands out as the dominant force due to its widespread adoption and reliability in amplifying DNA for various tests. PCR's established protocols and compatibility with multiple testing scenarios make it a preferred choice. In contrast, CRISPR Technology is emerging as a notable player, leveraging its unique gene-editing capabilities to enhance diagnostic precision and speed. The growing interest in personalized medicine and rapid testing solutions is driving the adoption of CRISPR, positioning it as a formidable competitor to traditional methods. As the market evolves, these technologies will define diagnostic capabilities in diverse healthcare settings.

Get more detailed insights about Point-of-Care Molecular Diagnostics Market Research Report—Global Forecast till 2035

Regional Insights

The Global Point of Care Molecular Diagnostics Market is witnessing significant growth across various regions, with North America leading the way, valued at 2.75 USD Billion in 2024 and projected to reach 6.5 USD Billion by 2035, indicating its majority holding in the market. Europe follows, with a valuation of 1.5 USD Billion in 2024 and expected growth to 3.8 USD Billion by 2035, reflecting the region's robust healthcare infrastructure and innovation in diagnostic technologies.

The Asia-Pacific (APAC) region accounts for a valuation of 1.75 USD Billion in 2024 and is projected to grow to 3.5 USD Billion by 2035, benefiting from increasing investments in healthcare and rising demand for rapid testing solutions. South America, with a valuation of 0.75 USD Billion in 2024, and the Middle East and Africa (MEA) at 0.5 USD Billion in the same year, showcase lower yet significant growth potential, emphasizing the need for more accessible diagnostic options in these regions.

The anticipated advancements in technologies and increasing awareness of early disease detection are expected to drive the growth of the Global Point of Care Molecular Diagnostics Market across these diverse regions, presenting ample opportunities for stakeholders in the industry.

Point of Care Molecular Diagnostics Market Region

Key Players and Competitive Insights

The competitive landscape of the Global Point of Care Molecular Diagnostics Market is characterized by rapid advancements in technology, increasing demand for efficient diagnostic solutions, and a heightened focus on patient-centric healthcare. Key players are striving to enhance their product offerings by integrating advanced molecular techniques that provide more rapid and accurate results, crucial for timely patient management. The adoption of these innovative diagnostic tools is propelled by a growing emphasis on decentralized healthcare, allowing testing to occur closer to the patients rather than centralized laboratories.

As the market continues to evolve, competition is driven by factors such as regulatory approval processes, technological innovation, and strategic partnerships or acquisitions aimed at enhancing market reach and product availability. Hologic has established a significant presence in the Global Point of Care Molecular Diagnostics Market by leveraging its strengths in innovative technologies and a focus on women's health. The company's commitment to developing cutting-edge molecular diagnostic products has positioned it to cater to the increasing need for quick and reliable test results.

Hologic's unique value proposition lies in its ability to integrate advanced technology with user-friendly interfaces, ensuring that healthcare providers can easily implement its solutions in diverse clinical settings. The company's emphasis on regulatory compliance and quality assurance enhances its reputation and fosters trust among healthcare professionals. This strategic positioning enables Hologic to address a broad consumer base effectively and respond adeptly to evolving market demands.BD is another key player in the Global Point of Care Molecular Diagnostics Market, known for its robust portfolio of diagnostic solutions that encompass various infectious diseases and healthcare-associated infections.

The company's strengths are rooted in its extensive research and development capabilities, allowing BD to introduce innovative products that significantly improve diagnostic accuracy and efficiency. BD's market presence is reinforced by strategic partnerships and collaborations, enhancing its ability to expand its product offerings and cater to emerging healthcare needs globally. The company’s key products include rapid testing platforms and molecular assays that facilitate timely clinical decisions.

Recent mergers and acquisitions have further bolstered BD's competitive edge by integrating new technologies and expertise, enabling the company to maintain a leadership position in the marketplace while driving growth through enhanced service offerings and market expansion strategies.

Key Companies in the Point of Care Molecular Diagnostics Market market include

Industry Developments

The Global Point of Care Molecular Diagnostics Market has seen significant advancements recently, with key players like Hologic, BD, and Roche driving growth through innovative product launches and strategic partnerships. The demand for rapid testing solutions, especially amid ongoing health crises, has propelled companies to expand their offerings. Notably, in July 2023, Siemens Healthineers acquired Varian Medical Systems, which will enhance their capabilities in molecular diagnostics. Additionally, Thermo Fisher Scientific and BioMérieux have announced collaborations to improve diagnostic efficiency.

The market valuation has soared, reflecting a heightened focus on disease management and personalized medicine, with an expected CAGR of over 10% in the coming years. Major happenings include the introduction of new multiplex testing platforms in early 2022, enhancing the speed and accuracy of disease detection. Moreover, Abbott's launch of portable molecular testing solutions has set benchmarks for convenience and accessibility. Such advancements not only signify technological evolution but also underscore a commitment to improving patient outcomes globally, demonstrating a collaborative approach among leading firms in the sector.

Future Outlook

Point of Care Molecular Diagnostics Market Future Outlook

The Point of Care Molecular Diagnostics Market is projected to grow at 8.28% CAGR from 2024 to 2035, driven by technological advancements, increasing demand for rapid testing, and rising healthcare expenditure.

New opportunities lie in:

Development of portable molecular testing devices for remote areas.
Integration of AI for enhanced diagnostic accuracy and efficiency.
Expansion of telehealth services incorporating molecular diagnostics.

By 2035, the market is expected to be robust, driven by innovation and increased accessibility.

Market Segmentation

Point of Care Molecular Diagnostics Market Type Outlook

PCR Tests
Nucleic Acid Amplification Tests
Microarray
Next-Generation Sequencing
Other Genetic Tests

Point of Care Molecular Diagnostics Market End Use Outlook

Hospitals
Diagnostic Laboratories
Home Care Settings
Outpatient Clinics

Point of Care Molecular Diagnostics Market Technology Outlook

Isothermal Amplification
Polymerase Chain Reaction
Sanger Sequencing
CRISPR Technology

Point of Care Molecular Diagnostics Market Application Outlook

Infectious Diseases
Genetic Testing
Cancer Diagnosis
Metabolic Disorders

Report Scope

MARKET SIZE 2024	6.248(USD Billion)
MARKET SIZE 2025	6.765(USD Billion)
MARKET SIZE 2035	14.99(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR)	8.28% (2024 - 2035)
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR	2024
Market Forecast Period	2025 - 2035
Historical Data	2019 - 2024
Market Forecast Units	USD Billion
Key Companies Profiled	Market analysis in progress
Segments Covered	Market segmentation analysis in progress
Key Market Opportunities	Integration of artificial intelligence enhances diagnostic accuracy in the Point of Care Molecular Diagnostics Market.
Key Market Dynamics	Technological advancements drive rapid adoption of Point of Care Molecular Diagnostics, enhancing patient outcomes and healthcare efficiency.
Countries Covered	North America, Europe, APAC, South America, MEA